Swetala v. Quten Research Institute, LLC

Summary

The United States District Court for the Eastern District of California considers Quten Research Institute, LLC’s motion to dismiss claims arising from allegedly misleading dosage representations on Qunol dietary-supplement labels. The court denies dismissal of the consumer-protection, negligent-misrepresentation, and intentional-misrepresentation claims, but grants dismissal with leave to amend of the express- and implied-warranty claims and the quasi-contract/unjust-enrichment claim. The court also addresses judicial notice and standing-related issues concerning the requested relief.

Holdings

1. The court granted judicial notice of the existence of the retail websites, product labels, and pricing information incorporated by reference into the complaint, but not of the truth of disputed substantive facts contained in those materials.
2. The complaint plausibly alleged that a reasonable consumer could be misled by Qunol front labels displaying a specific dosage and the number of capsules, gummies, or chews without stating whether the dosage was per unit or per serving. The court denied dismissal of the UCL, FAL, and CLRA claims.
3. The complaint failed to state express- or implied-warranty claims because the dosage representation was not a specific and unequivocal affirmation that each capsule contained the advertised dosage. The court granted dismissal with leave to amend.
4. The complaint adequately pleaded intentional and negligent misrepresentation claims, including scienter and intent to defraud, and the court denied dismissal of those claims.
5. The complaint failed to state a quasi-contract or unjust-enrichment claim because it did not allege that Plaintiff lacked an adequate remedy at law. The court granted dismissal with leave to amend.
6. Plaintiff plausibly alleged an actual and imminent threat of future injury sufficient to establish standing to seek injunctive relief because he alleged that he would like to purchase Quten's products again if their labels were truthful and consistent with their ingredients. The court denied dismissal of the request for injunctive relief.

Questions Presented

1. Whether the court could take judicial notice of retail websites and product-label information incorporated by reference into the complaint on a motion to dismiss.
2. Whether the complaint plausibly alleged that reasonable consumers were likely to be deceived by Qunol product front labels stating a dosage and the number of units without specifying whether the dosage was per unit or per serving.
3. Whether the dosage representations plausibly constituted an express warranty and supported an implied-warranty claim.
4. Whether the complaint adequately pleaded the elements of intentional and negligent misrepresentation, including scienter and intent to defraud.
5. Whether the complaint stated a quasi-contract or unjust-enrichment claim despite failing to allege the inadequacy of legal remedies.
6. Whether Plaintiff had Article III standing to seek prospective injunctive relief after learning that the advertised dosage was not provided in each capsule.

Disposition

other